Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine

Pediatric Infectious Disease Journal

Volumn 28, Issue 5, 2009, Pages 385-390

  Wong, Sharon H ^a   Lennon, Diana R ^a   Jackson, Catherine M ^a   Stewart, Joanna M ^a   Reid, Stewart ^b,d   Ypma, Ellen ^c   O'Hallahan, Jane M ^d   Oster, Philipp ^c   Mulholland, Kim ^e   Martin, Diana R ^f  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Ropata Village Medical Centre   (New Zealand)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^d MINISTRY OF HEALTH   (New Zealand)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

Author keywords

Immunization schedule; Infant; Serogroup B meningococcal outer membrane vesicle vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE VESICLE MENINGOCOCCAL VACCINE; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; FEEDING BEHAVIOR; FEVER; HUMAN; IMMUNOGENICITY; INFANT DISEASE; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE SWELLING; IRRITABILITY; MEMBRANE VESICLE; MENINGITIS; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS SEROGROUP B; NEISSERIA MENINGITIDIS STRAIN NZ98/254; NEW ZEALAND; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEROTYPE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; VOMITING;

EID: 67649525288     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318195205e     Document Type: Article

References (36)

1. Harrison LH. Vaccine prevention of meningococcal disease: making slow progress. Clin Infect Dis. 2006;43:1395-1397.
2. Granoff D, Feavers I, Borrow R. Meningococcal Vaccines. In: Plotkin S, Orenstein W, eds. Vaccines. 4th ed. Philadelphia, PA: Saunders; 2004:959-987.
3. Pollard AJ, Levin M. Vaccines for prevention of meningococcal disease. Pediat Infect Dis J. 2000;19:333-344. quiz 45.
4. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969; 129:1327-1348.
5. Goldschneider I, Gotschlich EC, Artenstein MS. Human Immunity to the Meningococcus. I: the role of humoral antibodies. J Exp Med. 1969;129: 1307-1326.
6. Trotter C, Findlow J, Balmer P, et al. Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England. Clin Vaccine Immunol. 2007;14:863-868.
7. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of an outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338:1093-1096.
8. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine. 1995;13:821-829.
9. de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992; 340:1074-1078.
10. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int J Epidemiol. 1995;24:1050-1057.
11. Sierra GVG, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Annals. 1991;14:195-207.
12. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 Sero-group B Outer-Membrane Protein Meningococcal Vaccines: a Randomised Controlled Trial in Chile. JAMA. 1999;281:1520-1527.
13. Martin DR, Walker SJ, Baker MG, et al. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis. 1998;177:497-500.
14. Dyet K, Devoy A, McDowell R, et al. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Vaccine. 2005;23:2228-2230.
15. Martin D, McDowell R. The Epidemiology of Meningococcal Disease in New Zealand in 2001. New Zealand Ministry of Health, Wellington: Prepared for the Ministry of Health by the Institute of Environmental Science and Research Limited (ESR); 2002.
16. Sexton K, Lennon D, Oster P, et al. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. The New Zealand Medical Journal. 2004;117 No1200:URL. Available at: http://www.nzma.org. nz/journal/117-1200/015/.
17. Thornton V, Lennon D, Rasanathan K, et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine. 2006;24:1395-1400.
18. Hosking J, Rasanathan K, Mow FC, et al. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens. Clin Vaccine Immunol. 2007;14:1393-1399.
19. Wong S, Lennon D, Jackson C, et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr Infect Dis J. 2007;26:345-350.
20. Jackson CM, Lennon DR, Sotutu VT, et al. Phase II Meningococcal B Vesicle Vaccine Trial in New Zealand infants. Arch Dis Child. 2008. In Press [epub ahead of print].
21. New Zealand Ministry of Health. Report on Maternity. Maternal and Newborn Information 2002. Wellington, New Zealand; 2004.
22. Ministry of Health. Immunisation Handbook 2006: Wellington, New Zealand.
23. Martin D, McCallum L, Glennie A, et al. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine. 2005;23:2218-2221.
24. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine. 2003;21:734-737.
25. Milagres LG, Ramos SR, Sacchi CT, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun. 1994;62:4419-4424.
26. Martin D, McDowell R. The Epidemiology of Meningococcal Disease in New Zealand in 2002. New Zealand Ministry of Health, Wellington: prepared for the Ministry of Health by the Institute of Environmental Science and Research Limited (ESR); 2003.
27. Martin D, McDowell R. The Epidemiology of meningococcal disease in New Zealand in 2003. New Zealand Ministry of Health, Wellington: prepared for the Ministry of Health by the Institute of Environmental Science and Research Limited (ESR); 2004.
28. Borrow R, Aaberge I, Santos G, et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol. 2005;12:970-976.
29. Cartwright K, Morris R, Rumke H, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine. 1999;17:2612-2619.
30. de Kleijn ED, de Groot R, Lafeber AB, et al. Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory. J Infect Dis. 2001;184:98-102.
31. Robinson T, Bullen C, Humphries W, et al. The New Zealand Hepatitis B screening programme: screening coverage and prevalence of chronic hepatitis B infection. NZ Med J. 2005;118(1221).
32. Greenberg DP, Vadheim CM, Wong VK, et al. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. Pediatr Infect Dis J. 1996;15:590-596.
33. West DJ. Clinical experience with hepatitis B vaccines. Am J Infect Control. 1989;17:172-180.
34. West DJ, Calandra GB, Hesley TM, et al. Control of hepatitis B through routine immunization of infants: the need for flexible schedules and new combination vaccine formulations. Vaccine. 1993;11(suppl 1):S21-S27.
35. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(suppl 1):S58-S67.
36. Kelly C, Arnold R, Galloway Y, et al. A prospective study of the effectiveness of the New Zealand Meningococcal B vaccine. Am J Epidemiol. 2007;166:817-823.